SCHEMBL3000502

SCHEMBL3000502

O=S(=O)(c1ccc(F)c(Cl)c1)N1CCN(c2nc(-c3ccc(Cl)cc3Cl)cs2)CC1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AR P10275 5/20 0.58
SMN1; SMN2 Q16637 3/20 0.56
ALDH1A1 P00352 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
MAPT P10636 6/20 0.48
USP2 O75604 1/20 0.48
RECQL P46063 1/20 0.48
HSD17B10 Q99714 1/20 0.48
POLB P06746 2/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
LMNA P02545 4/20 0.45
MAPK1 P28482 2/20 0.44
NPSR1 Q6W5P4 2/20 0.43
GBA1 P04062 1/20 0.41
TP53 P04637 1/20 0.40
ALOX12 P18054 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2997717 0.92 AR (0.60) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3654361 0.91 AR (0.52) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3022480 0.91 SMN1; SMN2 (0.69) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3006931 0.91 AR (0.64) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3017855 0.88 AR (0.56) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3011149 0.88 SMN1; SMN2 (0.71) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3014955 0.88 AR (0.60) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3014225 0.87 AR (0.63) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3013101 0.87 AR (0.59) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3012928 0.87 AR (0.59) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885SMN1; SMN2 1/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.